Core Insights - Recent Phase 2 topline results indicate NS002's potential for best-in-class epinephrine delivery, showing statistically significant improvements in early absorption compared to EpiPen®; a pivotal study is planned for Q4 2026 [1][6] - The company is advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic disorders) toward first-in-human studies expected to start in the second half of 2026, expanding its intranasal product portfolio into high-value therapeutic areas [1][4] - The company is well-funded through the planned NS002 pivotal study and potential NDA submission, with cash, cash equivalents, and marketable securities of $4.3 million as of December 31, 2025, up from $0.3 million in 2024 [7] Business Update - NS002 is an intranasal powder formulation of epinephrine for anaphylaxis, demonstrating significant improvements in time to therapeutic threshold (T100) and a higher proportion of participants reaching therapeutic levels quickly compared to EpiPen® [6] - The pivotal clinical study for NS002 is expected to initiate in Q4 2026, with a readout planned for Q1 2027, subject to regulatory alignment [6] - The company is also advancing NS005, targeting cardiovascular diseases, alongside NS003 and NS004 [2][6] Financial Results - Research and development expenses for the year ended December 31, 2025, were $2.4 million, compared to $0.3 million in 2024, primarily due to NS002 development costs [8] - General and administrative expenses increased to $2.7 million in 2025 from $0.7 million in 2024, attributed to the transition to a public company [9] - The net loss for the year ended December 31, 2025, was $5.9 million, compared to a net loss of $1.5 million in 2024, with 9,015,383 shares outstanding as of December 31, 2025 [9]

Core Insights - Nasus Pharma presented strong topline results from its Phase 2 clinical study of NS002, an intranasal epinephrine powder for treating anaphylaxis, demonstrating a significant advantage over EpiPen in time to therapeutic threshold [1][4]. Study Results - NS002 achieved effective epinephrine levels in a median of 1.69 minutes, compared to 3.42 minutes for EpiPen, with 67.4% of participants reaching therapeutic levels at 2.5 minutes versus 27.1% for EpiPen [2][18]. - The study showed NS002 consistently delivered faster and greater epinephrine exposure compared to intramuscular injection, while maintaining a comparable peak concentration and a favorable safety profile [3][16]. Clinical Performance - The Phase 2 study involved 50 healthy adults and evaluated NS002 under real-world conditions, including nasal congestion and repeat dosing scenarios, confirming its potential for practical use [14][15]. - NS002's pharmacokinetic profile demonstrated a T100 that is twice as fast as EpiPen, with 88.4% of subjects achieving the therapeutic threshold within 5 minutes compared to 64.6% for EpiPen [19][25]. Safety Profile - NS002 was well-tolerated with no serious adverse events reported, and most adverse events were mild and self-resolving, consistent with previous studies [16][23]. Future Plans - Based on the compelling results, Nasus Pharma plans to advance NS002 toward a pivotal study expected to initiate in the fourth quarter of 2026, highlighting its potential as a strategic asset for the company [4][27].

Core Insights - NS002 has shown potential to outperform EpiPen in terms of therapeutic threshold achievement, with a median time of 1.6 minutes to reach the critical 100 pg/mL epinephrine threshold [1] - The Phase 2 study results indicate a favorable safety profile for NS002, with no serious adverse events reported [2] Group 1: Study Results - At the five-minute mark, 88.4% of subjects receiving NS002 reached the epinephrine threshold compared to 64.6% with EpiPen [2] - Interim data from January showed that 91% of participants administered NS002 reached the 100 pg/mL threshold at 5 minutes, while only 67% of EpiPen users did [2] - NS002 demonstrated a higher mean peak plasma concentration (Cmax) of 655 pg/mL compared to 548 pg/mL for EpiPen [3] Group 2: Stock Performance - Nasus Pharma's stock is currently trading 45.1% below its 20-day simple moving average (SMA) and 60.1% below its 100-day SMA, indicating significant weakness [4] - Over the past 12 months, shares have decreased by 66.18%, positioning them closer to their 52-week lows than highs [4] - As of Wednesday, shares were down 5.02% at $2.65, near the 52-week low of $2.60 [6] Group 3: Technical Indicators - The RSI is at 28.58, indicating oversold territory and suggesting potential undervaluation in the short term [5] - The MACD is at -0.5581, below its signal line of -0.4248, indicating bearish pressure on the stock [5] - The combination of oversold RSI and bearish MACD suggests mixed momentum, with the overall trend remaining negative [5]

Summary of Nasus Pharma Conference Call Company Overview - **Company**: Nasus Pharma - **Product**: NS002, an intranasal powder epinephrine product candidate designed to treat anaphylaxis - **Technology**: Proprietary powder technology called Nasax, which enhances drug absorption compared to traditional liquid formulations [2][3] Industry Context - **Current Standard of Care**: Epinephrine intramuscular auto-injectors (e.g., EpiPen) are commonly used for anaphylaxis treatment, but many patients do not carry them due to needle phobia and device bulkiness [4] - **Market Research Insights**: 90% of allergists prioritize speed of onset when prescribing epinephrine products, with 87% considering T100 (time to therapeutic threshold) clinically meaningful [4][5] Key Findings from Phase 2 Study - **Study Design**: Involved 50 healthy adults with allergic rhinitis, assessing NS002 under normal conditions and nasal congestion [6] - **Pharmacokinetic Results**: - NS002 achieved T100 in a median of 1.69 minutes compared to 3.42 minutes for EpiPen, indicating a statistically significant improvement [9][12] - At 2.5 minutes, 67% of NS002 subjects reached the therapeutic threshold versus 27% for EpiPen; at 5 minutes, 88% for NS002 versus 64% for EpiPen [10][12] - NS002 demonstrated 60% higher total epinephrine absorption in the critical 10-minute window compared to EpiPen [13] - **Safety Profile**: NS002 was well-tolerated with no serious adverse events reported; most adverse events were mild and self-resolving [11][13] Competitive Advantages - **Speed of Onset**: NS002's rapid absorption is crucial for emergency situations, potentially reducing the need for repeat doses [8][11] - **Device Design**: NS002 is a compact, needle-free device that is easy to carry, enhancing patient convenience and compliance [4][54] - **Shelf Life**: The dry powder formulation offers enhanced stability and longer shelf life compared to liquid formulations [54] Future Development Plans - **Pivotal Study**: Planned for initiation in Q4 2026, with top-line data expected by Q1 2027; will include comparisons to EpiPen and intramuscular adrenaline [15][39][56] - **Regulatory Strategy**: The company aims to submit an NDA in the second half of 2027, focusing on demonstrating comparability to EpiPen for FDA approval [39][48] Market Potential - **Physician Acceptance**: There is openness among allergists to switch patients to needle-free options, indicating potential market uptake for NS002 [18] - **Best-in-Class Potential**: The company believes NS002 could be a best-in-class treatment based on its pharmacokinetic profile and performance compared to existing products [23][24] Additional Considerations - **Publication Plans**: The company intends to publish study data in a peer-reviewed journal and present at major allergy conferences [30][31] - **Comparative Analysis**: While comparisons to other products like Neffy were discussed, the focus remains on NS002's superior profile based on available data [37] This summary encapsulates the critical insights and developments discussed during the conference call, highlighting the potential of Nasus Pharma's NS002 in the anaphylaxis treatment landscape.

Core Insights - Nasus Pharma's NS002 demonstrated significantly faster absorption of epinephrine compared to EpiPen®, achieving the critical 100 pg/mL threshold in a median of 1.69 minutes versus 3.42 minutes [1][2][5] - The company plans to initiate a pivotal clinical study for NS002 in the fourth quarter of 2026 [2][4] Group 1: Clinical Study Results - The Phase 2 study enrolled 50 healthy adults, showing NS002's advantages in various administration scenarios during anaphylactic emergencies [3] - At 2.5 minutes, 67.4% of NS002 participants reached the therapeutic threshold compared to 27.1% with EpiPen® [5] - By 10 minutes, approximately 95% of NS002 participants reached the therapeutic threshold, indicating superior performance [5] Group 2: Pharmacokinetic and Pharmacodynamic Advantages - NS002 reached peak concentration in a median of 15 minutes, faster than EpiPen®'s 19.8 minutes [5] - Total epinephrine absorption in the critical 10-minute window was about 50% higher with NS002 compared to EpiPen® [5] - Repeat doses of NS002 maintained pharmacokinetic advantages, crucial for patients needing additional doses during severe anaphylaxis [5][6] Group 3: Safety Profile - NS002 exhibited a favorable safety and tolerability profile, with no serious adverse events reported [6] - The study results suggest NS002 could outperform EpiPen® in real-world conditions, including challenging scenarios [6] Group 4: Company Overview - Nasus Pharma is focused on developing innovative intranasal products, with NS002 as a needle-free alternative for anaphylaxis treatment [8] - The proprietary Nasax® powder platform is designed for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network [8]

Core Insights - Nasus Pharma Ltd. is set to host a conference call and webcast on March 16, 2026, to present the topline analysis from the Phase 2 repeated dose clinical study of NS002, an intranasal powder epinephrine product candidate [1] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal powder products for acute medical conditions [4] - The NS002 product is being developed as a needle-free alternative to epinephrine autoinjectors for patients experiencing anaphylaxis [4] - The company's proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [4] - The PBI formulation employs uniform spherical powder particles for broad dispersion and potentially faster absorption compared to liquid-based nasal products [4] Conference Call Details - The conference call will take place at 8:00 a.m. ET on March 16, 2026, and will include a question-and-answer session following the data presentation [1] - Individuals can register for the webcast through a provided link, and dial-in numbers for the conference call are available for both US and international participants [6]

Core Viewpoint - Nasus Pharma Ltd. is participating in the upcoming virtual Life Sciences Investor Forum, showcasing its innovative intranasal products aimed at treating emergency medical conditions [1]. Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions [3]. - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative to traditional autoinjectors for anaphylaxis treatment [3]. - The proprietary powder-based intranasal (PBI) technology enables rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [3]. - The PBI formulation features uniform spherical powder particles, which may allow for broader dispersion and potentially faster absorption compared to liquid-based nasal products [3]. Presentation Details - Company management will be available for one-on-one meetings during the conference, and interested parties are encouraged to arrange meetings through their conference representative [2]. - The presentation is scheduled for March 11, 2026, at 12:30 p.m. ET, and will be led by CEO Dan Teleman [4].

A NEW FRONTIER IN INTRANASAL DRUG DELIVERY A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products Company Presentation – February 2026 Ticker NSRX Exchange NYSE American Please migrate color palette to match website Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the "Company", "Nasus" or "Nasus Pharma") contains "forward-looking statements" within the meaning of the Private Securities Lit ...

Core Viewpoint - Nasus Pharma Ltd. has successfully closed a private placement of ordinary shares and warrants, raising approximately $15.0 million to advance its clinical development programs, particularly the NS002 intranasal epinephrine product candidate [1][3]. Group 1: Private Placement Details - The private placement involved the sale of 2,695,425 ordinary shares and accompanying warrants at a combined purchase price of $5.565 per share [3][5]. - Citizens Capital Markets acted as the lead placement agent, with Laidlaw & Company (UK) Ltd. serving as the co-placement agent [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized to advance the pivotal clinical development of NS002 for anaphylaxis treatment, initiate first-in-human studies for other products, and for general corporate purposes [5]. Group 3: Product Development Focus - NS002 is being developed as a needle-free alternative to epinephrine autoinjectors, aimed at providing rapid drug delivery in emergency situations [8]. - The company is focused on leveraging its proprietary intranasal technology across various therapeutic areas to enhance clinical value [3][8]. Group 4: Financial Strengthening - The financing is expected to significantly strengthen the company's balance sheet and provide funding visibility for planned operations and development activities [3][5]. Group 5: Warrants Information - The warrants have an exercise price of $6.53 per share, are immediately exercisable, and will expire two years from issuance or 30 trading days after the announcement of NS002 pivotal study results [4].

Core Insights - Nasus Pharma's NS002 shows significantly faster absorption and higher peak epinephrine levels compared to EpiPen, with 91% of participants achieving the 100 pg/ml plasma threshold at 5 minutes versus 67% for EpiPen [1][3] - The interim results indicate that NS002 is well-tolerated with no serious adverse events reported, and the pharmacodynamic response is comparable to EpiPen [1][5] - Full Phase 2 results are expected by the end of Q1 2026, with a pivotal study initiation planned for Q4 2026 [1][7] Study Design - The open-label Phase 2 study enrolled 50 healthy adults with a history of allergic rhinitis, divided into two cohorts [2] - The first cohort of 25 participants received NS002 or EpiPen with and without a nasal allergic challenge, while the second cohort received repeat doses under similar conditions [2] Key Interim Results - NS002 achieved a mean peak plasma concentration (Cmax) of 655 pg/ml compared to 548 pg/ml for EpiPen, with a peak concentration (Tmax) reached in 10.8 minutes versus 15 minutes for EpiPen [3] - Total epinephrine absorption in the critical 10-minute window was higher for NS002 (AUC: 55 h*pg/ml) compared to EpiPen (AUC: 32 h*pg/ml) [3] Safety and Tolerability - NS002 was well-tolerated, with 95% of treatment-emergent adverse events being mild and self-resolving, primarily local [5] - The pharmacodynamic response, including changes in blood pressure and pulse rate, remained within normal ranges and was comparable to EpiPen [5] Expert Commentary - Clinical experts highlight the potential of NS002 as a significant advancement in anaphylaxis treatment due to its faster delivery and higher concentrations of epinephrine [6] - The needle-free administration of NS002 could address compliance challenges associated with current treatments [6] Future Plans - Nasus Pharma aims to complete the Phase 2 study by the end of Q1 2026 and plans to initiate its pivotal clinical study in Q4 2026 [7]